Edoxaban versus Warfarin in high-risk patients with atrial fibrillation
pubmed.ncbi.nlm.nih.gov › ...
While underuse of anticoagulation in high-risk patients with AF remains common, substitution of effective and ... Baris Gencer , Alon Eisen , David Berger ...
People also ask
Who are high risk patients with atrial fibrillation?
How effective is Evolocumab on cardiovascular outcomes in patients with recent myocardial infarction?
Dr. Emre Gençer is a Principal Research Scientist at MIT Energy Initiative with more than… · Experience: Sesame Sustainability · Education: Purdue ...
Apr 4, 2022 · The new paradigm requires integrated, system-based risk assessments and interventions that address current and future hazards throughout entire ...
Effect of Long-Term Marine ɷ-3 Fatty Acids Supplementation ... - PubMed
pubmed.ncbi.nlm.nih.gov › ...
Background: Some, but not all, large-scale randomized controlled trials (RCTs) investigating the effects of marine ɷ-3 fatty acids ...
Oct 6, 2021 · ... Gencer B, Siddiqi HK, Ng C, Gibson H, et al . Effect of marine omega-3 fatty acid and vitamin D supplementation on incident atrial ...
May 20, 2020 · Gencer B, Mach F, Murphy SA, et al. Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: A ...
His research focuses on integration of emerging and conventional energy technologies, their policy implications, multiscale modeling, and optimization. He is ...
Missing: et | Show results with:et
Ebru Gencer - Senior Urban Resilience Adviser - The World Bank
www.linkedin.com › ebru-gencer-8179a55
Ebru Gencer is a researcher, scholar, and practitioner on urban risk, climate resilience, and sustainable development. She is the Founding Director of the ...
No information is available for this page. · Learn why
11. The Court recalls that identical complaints were raised by applicants in the cases of Emin and Others v Cyprus, no. 59623/08 et al, decision of 3 April 2012 ...